Literature DB >> 19906198

Structural difference in the complement activation site of human IgG1 and IgG3.

T E Michaelsen1, I Sandlie, D B Bratlie, R H Sandin, O Ihle.   

Abstract

The C1q binding epicentre on IgG molecules involves residues Asp(270), Lys(322), Pro(329) and Pro(331) in the C(H)2 domain. IgG1 and IgG3 are usually the most efficient of the four human IgG subclasses in activating complement and they both share all these residues. To reveal possible differences in the structural requirement for complement activation, we created a number of NIP (5-iodo-4-hydroxy-3-nitro-phenacetyl) specific IgG1 and IgG3 antibodies with parallel mutations in or near the putative C1q binding site. The mutants were tested simultaneously for antibody induced, antibody-dependent complement-mediated lysis (ADCML) at high and low antigen concentration on the target cells using sera of human, rabbit and guinea pig as complement source. In addition, we tested the antibodies against target cells decorated with the NP hapten, which has 10-fold lower affinity for the antibodies compared to the NIP hapten. We also used ELISA methods to measure complement activation. We observed a clear difference between IgG1 and IgG3 localized to residues Asp(270), Leu(334), Leu(335). For all these residues, and especially for Asp(270), IgG1 was heavily reduced in complement activation, while IgG3 was only moderated reduced, by alanine substitution. This difference was independent of the long hinge region of IgG3, demonstrated by hinge region truncation of this isotype such that it resembles that of IgG1. This report indicates the presence of structural differences between human IgG1 and IgG3 in the C1q binding site, and points to a specialization of the two isotypes with respect to complement activation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19906198     DOI: 10.1111/j.1365-3083.2009.02338.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  22 in total

1.  Combined roles of human IgG subclass, alternative complement pathway activation, and epitope density in the bactericidal activity of antibodies to meningococcal factor h binding protein.

Authors:  Serena Giuntini; Donald C Reason; Dan M Granoff
Journal:  Infect Immun       Date:  2011-11-07       Impact factor: 3.441

2.  Fc Engineering of Human IgG1 for Altered Binding to the Neonatal Fc Receptor Affects Fc Effector Functions.

Authors:  Algirdas Grevys; Malin Bern; Stian Foss; Diane Bryant Bratlie; Anders Moen; Kristin Støen Gunnarsen; Audun Aase; Terje Einar Michaelsen; Inger Sandlie; Jan Terje Andersen
Journal:  J Immunol       Date:  2015-04-22       Impact factor: 5.422

Review 3.  Endogenous IgG hypogammaglobulinaemia in critically ill adults with sepsis: systematic review and meta-analysis.

Authors:  Manu Shankar-Hari; Nicholas Culshaw; Benjamin Post; Eduardo Tamayo; David Andaluz-Ojeda; Jesús F Bermejo-Martín; Sebastian Dietz; Karl Werdan; Richard Beale; Jo Spencer; Mervyn Singer
Journal:  Intensive Care Med       Date:  2015-05-14       Impact factor: 17.440

4.  Human Factor H Domains 6 and 7 Fused to IgG1 Fc Are Immunotherapeutic against Neisseria gonorrhoeae.

Authors:  Jutamas Shaughnessy; Lisa A Lewis; Bo Zheng; Caleb Carr; Isaac Bass; Sunita Gulati; Rosane B DeOliveira; Severin Gose; George W Reed; Marina Botto; Peter A Rice; Sanjay Ram
Journal:  J Immunol       Date:  2018-09-28       Impact factor: 5.422

Review 5.  B-cell abnormalities in HIV-1 infection: roles for IgG3 and T-bet.

Authors:  Lela Kardava; Susan Moir
Journal:  Curr Opin HIV AIDS       Date:  2019-07       Impact factor: 4.283

6.  Human IgG1, IgG3, and IgG3 Hinge-Truncated Mutants Show Different Protection Capabilities against Meningococci Depending on the Target Antigen and Epitope Specificity.

Authors:  S Giuntini; D M Granoff; P T Beernink; O Ihle; D Bratlie; T E Michaelsen
Journal:  Clin Vaccine Immunol       Date:  2016-08-05

7.  Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions.

Authors:  Gregory L Moore; Hsing Chen; Sher Karki; Greg A Lazar
Journal:  MAbs       Date:  2010 Mar-Apr       Impact factor: 5.857

Review 8.  Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics.

Authors:  Josée Golay; Gianpietro Semenzato; Alessandro Rambaldi; Robin Foà; Gianluca Gaidano; Enrica Gamba; Fabrizio Pane; Antonello Pinto; Giorgina Specchia; Francesco Zaja; Mario Regazzi
Journal:  MAbs       Date:  2013-08-08       Impact factor: 5.857

9.  IgG3 regulates tissue-like memory B cells in HIV-infected individuals.

Authors:  Lela Kardava; Haewon Sohn; Christine Youn; James W Austin; Wei Wang; Clarisa M Buckner; J Shawn Justement; Valerie A Melson; Gwynne E Roth; Marissa A Hand; Kathleen R Gittens; Richard W Kwan; Michael C Sneller; Yuxing Li; Tae-Wook Chun; Peter D Sun; Susan K Pierce; Susan Moir
Journal:  Nat Immunol       Date:  2018-08-13       Impact factor: 25.606

10.  Igh locus structure and evolution in Platyrrhines: new insights from a genomic perspective.

Authors:  Diego Garzón-Ospina; Sindy P Buitrago
Journal:  Immunogenetics       Date:  2019-12-14       Impact factor: 2.846

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.